This MedLibrary.org supplementary page on Moraxella catarrhalis is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
| Moraxella catarrhalis | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scientific classification | ||||||||||||||
|
||||||||||||||
| Binomial name | ||||||||||||||
| Moraxella catarrhalis |
Moraxella catarrhalis is a gram-negative, aerobic, oxidase-positive diplococcus which may both colonize and cause respiratory tract-associated infection in humans.
M. catarrhalis was previously placed in a separate genus named Branhamella. The rationale for this was that other members of the genus Moraxella are rod-shaped and rarely caused infections in humans. However results from DNA hybridization studies and 16S rRNA sequence comparisons were used to justify inclusion of the species catarrhalis in the genus Moraxella. Consequently, the name Moraxella catarrhalis is currently preferred for these bacteria. Nevertheless, some in the medical field continue to call these bacteria Branhamella catarrhalis.
Moraxella is named after Victor Morax, a Swiss Ophthalmologist who first described this genus of bacteria. catarrhalis is derived from catarrh, originally a Greek word meaning 'to flow down', describing the profuse discharge from eyes and nose typically associated with severe inflammation in colds.
Clinically, these bacteria are known to cause bronchitis, sinusitis, laryngitis and otitis media. Elderly patients and long-term heavy smokers with chronic pulmonary disease should be aware that M. catarrhalis is associated with bronchopneumonia, as well as exacerbations of existing chronic obstructive pulmonary disease (COPD).
Treatment options include antibiotic therapy or a so-called "watchful waiting" approach. The great majority of clinical isolates of this organism produce beta-lactamases and are resistant to penicillin, with some suggestion of trimethoprim resistance in certain regions of the world. It is susceptible to trimethoprim-sulfamethoxazole (TMP-SMZ), fluoroquinolones, and most second and third generation cephalosporins. In addition, M. catarrhalis infection may be treated with erythromycin and amoxicillin-clavulanate (Augmentin).
The peak rate of colonisation by M. catarrhalis appears to occur at approximately 2 years of age, with a striking difference in colonisation rates between children and adults (very high to very low).
Current research priorities involve trying to find a suitable vaccine for this genotypically diverse organism, as well as determining factors involved with virulence e.g. complement resistance.
References
- Murray, P; Rosenthal, K, Pfaller, M. (2005). Medical Microbiology, 5th ed., Mosby, p. 365. ISBN 0-323-03303-2.
- Tierney, L. et al. (October 19, 2005). Current Medical Diagnosis and Treatment, 45th ed., McGraw Hill Medical, p. 1501. ISBN 0-07-145410-1.
Wikipedia content modification information:
- This page was last modified on 2 October 2008, at 19:12.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Moraxella catarrhalis".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.